Last $638.37 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:08 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/25/14 - $746.00
52 Week Low
11/4/14 - $615.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi-adr (SNYN) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2013.

sanofi-adr (SNYN) Key Developments

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma

Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. In the study, the three highest doses of dupilumab in combination with standard-of-care therapy met the primary endpoint of a statistically significant improvement from baseline in forced expiratory volume over one second at Week 12 in patients with high blood eosinophils, as compared to placebo in combination with standard-of-care therapy. In addition, two doses of dupilumab showed a statistically significant improvement in mean percentage change in FEV1, as well as a reduction in severe exacerbations, in both the high eosinophils and overall study population. In the high eosinophils patient group: Mean improvements from baseline in FEV1 at 12 weeks, the primary endpoint of the study were: 390ml dupilumab 300 mg every other week; 430 ml dupilumab 200 mg Q2W; 180 ml placebo. In the overall population: Mean improvements from baseline in FEV1 at 12 weeks were: 280 ml dupilumab 300 mg Q2W; 310 ml dupilumab 200 mg Q2W; 120 ml placebo. In both the high eosinophils patient group and overall patient group: Dupilumab showed a reduction in adjusted annualized rate of severe exacerbations compared to placebo. These results were based on a pre-specified interim analysis, which occurred when all patients had reached Week 12 of the 24-week treatment period; the average treatment duration at the time of the analysis was 21.5 weeks. The final analyses on exacerbations and safety will occur at 24 weeks. The most common adverse event was injection site reaction, which was more frequent in the four dupilumab dose groups compared to placebo. Other common adverse events in the study included upper respiratory tract infection, headache, nasopharyngitis and bronchitis. The incidence of infections was balanced across treatment groups, as was the incidence of serious adverse events. The double-blind, placebo-controlled, 24-week, dose-ranging study enrolled 776 adult patients with moderate-to-severe uncontrolled asthma, as defined by the Global Initiative for Asthma 2014 Guidelines. Trial participants were randomized to receive one of four doses of dupilumab or placebo. Approximately 40% of patients had high eosinophils across the dose groups. During the treatment period, patients continue their stable medium- or high-dose inhaled corticosteroid and long-acting beta agonist combination product. Patients can administer inhaled rescue medication as needed during the study. The 24-week treatment period of the study is ongoing, and patients will be followed for 16 weeks after treatment. Full results of the trial will be presented at an upcoming scientific meeting.

Sanofi Announces Management Changes

The Board of Directors held a meeting October 29, 2014 and decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher resigned as a director of Sanofi. Pending the decision on the appointment of a new Chief Executive Officer, the Board asked Serge Weinberg to fulfill jointly, as of now and on a temporary basis, the functions of Chairman and Chief Executive Officer. As soon as a new Chief Executive Officer will be appointed, the Group's governance will return to a Chairman and a separate Chief Executive Officer.

Sanofi Revises Earnings Guidance for the Full Year 2014

Sanofi announced revised earnings guidance for the full year 2014. The company revised guidance for the year, moved guidance from 5% to 7%, to 6% to 8%. The company continue to expect improvement in the gross margin compared to last year. The company continue to expect business EPS to grow between 6% and 8% on a full year basis 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $638.37 MXN 0.00

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.70 USD +0.64
Amgen Inc $164.72 USD +2.48
Bayer AG €119.15 EUR +1.33
Bristol-Myers Squibb Co $58.86 USD +0.34
Gilead Sciences Inc $100.30 USD -0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation SNYN Industry Range
Price/Earnings 24.5x
Price/Sales 3.0x
Price/Book 1.9x
Price/Cash Flow 15.0x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at